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BODINEJOURNAL 1
Functional Antagonism Between Vorinostat 
and Temozolomide when Combined with 
Ionizing Radiation (IR) in Glioblastoma
Background
Glioblastoma is the most common primary adult brain tumor. Surgery 
followed by radiation therapy in combination with temozolomide 
(Tmz) produces a median survival of 14.6 months. Tmz is a DNA 
akylating agent that leads to the mispairing of guanine residues 
with thymine. An intact mismatch-repair mechanism (MMR) 
converts the mispaired thymine into a lethal double-strand DNA 
break. Vorinostat (SAHA), an HDAC inhibitor, has been shown to 
act as a radiosensitizer, possibly through inhibition of DNA repair. 
SAHA has successfully been combined with a number of cytotoxic 
agents. We hypothesized that SAHA would further potentiate the 
radiosensitizing properties of Tmz in glioblastoma.
Materials/Methods
Experiments were performed with 2 glioblastoma cell lines (U87, 
LN18). DNA double strand breaks were quantified by both neutral 
comet assay and gamma-H2AX immunohistochemistry. Assays 
were performed immediately, and 24 hours after IR to assess DNA 
damage and repair respectively. For the neutral comet assay the 
dose of radiation was 30 Gy and the ‘olive moment’ was scored. 
The magnitude of the olive moment correlates with increasing
DNA damage. For gamma-H2AX assay, the dose of radiation was 
2 Gy and the percentage of cells with more than 3 foci was scored. 
Quantitative PCR and clonogenic cell survival were performed using 
standard techniques.
Results
In the absence of drug, radiation induced DNA-double strand breaks 
were almost completely repaired within 24-hours. In U87 both Tmz + 
IR, and SAHA + IR increased the olive moment compared to IR alone 
(24 hour post IR time-point). When Tmz and SAHA were combined 
together with IR, the olive moment decreased to 6.5 as compared to 
Tmz + IR alone 8.7 (p<0.05). Similarly, in the absence of IR, SAHA 
was found to decrease Tmz induced DNA damage. Comparable 
results were obtained with gamma-H2AX assay and with the LN18 
cell line. Clonogenic radiation survival assay demonstrated Tmz + 
SAHA to be no more effective than Tmz alone in potentiating the 
cytotoxic effect of IR. On qPCR, SAHA was found to down-regulate 
MLH1, MLH3, MSH2 and MSH 3, key genes involved in MMR.
Conclusion
Both Tmz and SAHA individually potentiated the effect of IR, 
inhibiting the repair of DNA double strand breaks. However, when 
cells were exposed to both drugs together less DNA damage was seen 
than with Tmz alone. Based upon qPCR data we hypothesize that 
SAHA down regulates the MMR pathway. Our work demonstrates 
that the addition of an HDAC inhibitor to cytotoxic agents may 
produce unexpected antagonism. 
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